Seventure Partners, a worldwide leading microbiome venture capital, and Clinical Microbiomics A/S, a pioneering microbiome research company, today announced the completion of a financing in the Danish growth company.
The transaction confirms Seventure Partners position as leading investor in the fast-developing microbiome field, where they have backed growth companies with funding through “Health for Life™ I” and “Health for Life™ II” since 2013.
Microbiome science is widely proposed as the next frontier in addressing our most urgent health challenges. Organisations worldwide are exploring the potential for microbiome science to help people live better lives; from novel nutritional products and next-generation probiotics to new ways to diagnose, treat and prevent disease. However, the complexity of microbiome science remains a challenge in bringing new solutions to market.
Since its foundation in 2015, Clinical Microbiomics has been innovating at the forefront of microbiome science. The company is working with the world’s leading food and consumer health companies and is supporting the pharmaceutical industry in phase 3 clinical trials through its GCP-compliant microbiome research services. Importantly Clinical Microbiomics hosts the richest data-warehouse on the market with 30k+ samples linking 3M+ bacterial strains to clinical phenotypes. Clinical Microbiomics is a premium quality microbiome analysis company, particularly known for its pioneering work on clonal-level microbiome profiling that is recognized as the most sensitive, precise, and comprehensive in the field.
Together with researchers from the world’s most prominent academic institutions and innovative companies, microbiome scientists at Clinical Microbiomics are constantly pushing the boundaries of science to find the answers needed to impact health and disease.
Isabelle de Cremoux, CEO and managing partner at Seventure Partners, commented: “Incredible progress has been made in understanding the link between the microbiota and our health in the past years, but there is still much more to be accomplished. There is a lot of data available, but we need better tools to get more insights and standards for how to put it to practice. Clinical Microbiomics has a track-record of developing tools that can untangle the complexity of the microbiome and help researchers worldwide understand the mechanisms that impact health and disease. Our investment will enable Clinical Microbiomics to invest even further to lead the way with innovative concepts and services at pharma standards for this field, and we believe their work will play a critical role in unleashing the potential of microbiome science”.
The funds raised will be invested to further advance Clinical Microbiomics’ leading microbiome profiling and systems biology platform, and to expand the service offering within multi-omics data integration, as well as to build further presence in key markets starting with the US.
Anders Grøn, CEO at Clinical Microbiomics, commented: “Our vision is a world where people are healthier because we understand how to improve our inner ecology – the microbiome. We challenge the idea that the complexity of the microbiome prevents us from exploring its potential to tackle the most pressing health questions of our time. Seventure Partners brings valuable experience across the microbiome field that will help us identify and address challenges across the sector, and their investment will enable us to expand our innovation programs, quality management systems, and strategic collaborations at a high pace to help researchers worldwide to bring new products and treatments to market.”
Clinical Microbiomics’ is located in Medicon Valley, one of the largest centres for microbiome research in the World, but the Company’s microbiome analysis services are offered worldwide to clients across sectors such as pharma, biotech, nutrition, food, feed, personal care, and consumer testing.
